| 前收盘价格 | 5.99 |
| 收盘价格 | 6.05 |
| 成交量 | 1,883,996 |
| 平均成交量 (3个月) | 3,552,049 |
| 市值 | 1,464,127,104 |
| 预期市盈率 (P/E Forward) | 33.11 |
| 价格/销量 (P/S) | 3.53 |
| 股市价格/股市净资产 (P/B) | 8.76 |
| 52周波幅 | |
| 利润日期 | 30 Apr 2026 |
| 营业毛利率 | -14.86% |
| 营业利益率 (TTM) | -49.04% |
| 稀释每股收益 (EPS TTM) | -0.230 |
| 季度收入增长率 (YOY) | 61.00% |
| 总债务/股东权益 (D/E MRQ) | 124.68% |
| 流动比率 (MRQ) | 4.12 |
| 营业现金流 (OCF TTM) | -47.54 M |
| 杠杆自由现金流 (LFCF TTM) | -17.22 M |
| 资产报酬率 (ROA TTM) | -6.58% |
| 股东权益报酬率 (ROE TTM) | -36.26% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Ardelyx, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 1.5 |
| 平均 | 1.30 |
|
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 2.51% |
| 机构持股比例 | 72.46% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Rock Springs Capital Management Lp | 31 Dec 2025 | 2,299,473 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 19.00 (Wedbush, 218.26%) | 购买 |
| 中 | 18.00 (201.51%) | |
| 低 | 17.00 (BTIG, 184.76%) | 购买 |
| 平均值 | 18.00 (201.51%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 5.74 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 23 Feb 2026 | 19.00 (218.26%) | 购买 | 5.75 |
| BTIG | 20 Feb 2026 | 17.00 (184.76%) | 购买 | 5.73 |
| 29 Jan 2026 | 17.00 (184.76%) | 购买 | 7.85 | |
| HC Wainwright & Co. | 20 Feb 2026 | 18.00 (201.51%) | 购买 | 5.73 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RAAB MICHAEL | - | 6.30 | -41,668 | -262,508 |
| 累积净数量 | -41,668 | |||
| 累积净值 ($) | -262,508 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 6.30 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RAAB MICHAEL | 职员 | 15 Apr 2026 | 自动卖出 (-) | 41,668 | 6.30 | 262,508 |
| RAAB MICHAEL | 职员 | 15 Apr 2026 | 执行期权 | 20,834 | - | - |
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Feb 2026 | 公告 | Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 |
| 03 Feb 2026 | 公告 | Ardelyx Receives New Patent for Tenapanor |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合